Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a report released on Monday,Benzinga reports. They presently have a $14.00 price objective on the stock. Chardan Capital’s price objective would suggest a potential upside of 211.80% from the stock’s current price.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, February 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a report on Wednesday, February 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, January 21st. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Coya Therapeutics Price Performance

NASDAQ COYA traded down $0.04 on Monday, reaching $4.49. The company had a trading volume of 140,310 shares, compared to its average volume of 208,863. Coya Therapeutics has a 1 year low of $3.94 and a 1 year high of $7.75. The firm has a 50-day moving average of $4.77 and a 200-day moving average of $5.59. The firm has a market capitalization of $93.93 million, a PE ratio of -4.04 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Tuesday, March 17th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.26). The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. As a group, sell-side analysts expect that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Coya Therapeutics

Institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. bought a new position in Coya Therapeutics in the third quarter valued at approximately $28,000. CIBC Private Wealth Group LLC bought a new position in shares of Coya Therapeutics during the 4th quarter worth approximately $47,000. Occudo Quantitative Strategies LP bought a new stake in Coya Therapeutics in the fourth quarter valued at $66,000. Lantern Wealth Advisors LLC bought a new stake in Coya Therapeutics in the 3rd quarter valued at about $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth approximately $81,000. Institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.